Reading FDMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FDMT free→Reading FDMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FDMT free→QuarterlyIQ Insights · FDMT
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(0.1) + peer(0.2*3.8) + term(0.0) → 0.81% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 7, 2026, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2026. A copy of 4DMT’s press release, titled “4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 18, 2026, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Results of Operations and Financial Condition. As of December 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $514 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and mar…
Results of Operations and Financial Condition. On November 10, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Results of Operations and Financial Condition. As of September 30, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $372.2 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and…
Results of Operations and Financial Condition. On August 11, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Results of Operations and Financial Condition. On May 8, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2025. A copy of 4DMT’s press release, titled “4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Results of Operations and Financial Condition. On February 28, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2024. A copy of 4DMT’s press release, titled “4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to